Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Other Non-current Assets
Long-term assets not reported separately.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Other non-current assets rises 157.2% from a year ago
Other non-current assets stood at $4.74M at the end of Q1 FY2026, up 157.2% from a year earlier and down 4.0% from the prior quarter. Over 3 fiscal years it compounded at +606.6% a year.
Context
- Other non-current assets amounted to 4.8% of total assets at the end of Q1 FY2026, up 3.6 pp from a year earlier.
- Other non-current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current assets keeps rising in the next quarterly balance sheet after a +157.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 4.94M USD
- Year-over-year change
- +87.5%
- 3-year CAGR
- +606.6%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.94M | +87.5% |
| FY2024 | 2024-12-31 | 2.64M | +20169.2% |
| FY2023 | 2023-12-31 | 13K | -7.1% |
| FY2022 | 2022-12-31 | 14K | — |
Other Non-current Assets vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's Mar 2026 other non-current assets of $4.74M is the highest of the 11 companies compared; the peer median is $247.5K.
- Its year-over-year change of +157.2% is the highest of 10, against a peer median of -21.4%.
- Other non-current assets amounts to 4.8% of total assets for AARD, versus a peer median of 0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $4.74M | +157.2% | +606.6% | 4.8% | |
| Mar 2026 | $3.79M | -21.4% | -7.2% | 2.8% | |
| Mar 2026 | $2.14M | -57.6% | +11.9% | 1.4% | |
ZURAZura Bio Limited | Mar 2026 | $1.51M | +116.6% | -24.3% | 0.7% |
| Mar 2026 | $1.18M | -0.3% | +2.1% | 0.7% | |
| Mar 2026 | $312K | +0.0% | -29.5% | 0.1% | |
| Mar 2026 | $183K | +39.7% | +17.0% | 0.2% | |
| Mar 2026 | $144K | -95.8% | -49.1% | 0.0% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $61.96K | -22.8% | +167.2% | 0.0% |
| Mar 2026 | $3K | -99.8% | -21.1% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding AARD) | $247.5K | -21.4% | -7.2% | 0.2% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.